🧫
AhR agonist effects on NEP expression in N2a cells
active
experiment
Created: 2026-04-10T14:45:43
By: etl-v1-backfill
Quality:
50%
✓ SciDEX
ID: exp-a3090cf0-854f-45dc-8ef7-06cf9a6bb754
🧫 Experiment Protocol
ExploratoryAlzheimer's diseaseNEPN2a cellsproposed
Investigation of how various aryl hydrocarbon receptor (AhR) agonists affect neprilysin (NEP) expression and enzyme activity in N2a neuroblastoma cells. The study tested both endogenous ligands (L-Kynurenine and FICZ) and exogenous ligands (diosmin and indole-3-carbinol) to determine their effects on NEP, a major endogenous catabolic enzyme of amyloid β. The experiment aimed to establish the cellular mechanisms by which AhR activation could potentially regulate Alzheimer's disease pathology through enhanced Aβ clearance.
PRIMARY OUTCOME
NEP expression and enzyme activity
EXPECTED OUTCOMES
1. The intervention targeting NEP shifts NEP expression and enzyme activity in the predicted direction relative to the matched control arm.
2. Secondary disease-relevant readouts in Alzheimer's disease remain directionally concordant with the primary endpoint rather than showing isolated single-assay effects.
3. The effect persists after adjustment for baseline covariates, batch effects, or repeated-measures structure used in the study design.
SUCCESS CRITERIA
- Prespecified primary endpoint (NEP expression and enzyme activity) improves versus control with p < 0.05 or an equivalent corrected threshold used by the study.
- The effect size is biologically meaningful and reproduced across technical/biological replicates or the validation subset.
- Safety, data quality, and missingness remain within protocol-defined bounds so the result is interpretable rather than driven by attrition or assay failure.
PROTOCOL
1. Establish N2a cells cohorts for Alzheimer's disease and predefine inclusion, exclusion, and quality-control criteria before intervention. 2. Apply the experimental manipulation described for NEP, alongside matched control or comparator arms, and document dose, exposure window, and sample timing in a locked protocol log. 3. Measure NEP expression and enzyme activity together with orthogonal secondary readouts such as molecular, imaging, behavioral, or safety endpoints that are appropriate to the title and study design. 4. Use blinded outcome assessment where feasible, prespecified statistical analysis, and replicate the core readout across biological replicates or an independent validation subset. 5. Interpret results against the baseline study rationale: Investigation of how various aryl hydrocarbon receptor (AhR) agonists affect neprilysin (NEP) expression and enzyme activity in N2a neuroblastoma cells. The study tested both endogenous ligands (L-Kynurenine and FICZ) and exogenous ligands (diosmin and indole-
LINKED HYPOTHESES
Source: PMID 34522212 ↗
🧫 Experiment Extras
PATHWAY
AhR signaling pathway
MARKET PRICE
$0.50
STATUS
proposed
▸Metadataorigin_type: v1_polymorphic_backfill
| origin_type | v1_polymorphic_backfill |
| source_table | experiments |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.